Clinical trials: Drug Withdrawal
Drug-withdrawal., Drug Abuse
Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.
INTRODUCTION. One of the main problems of the treatment of cocaine-dependent patients is the high rate of relapses occurs within the first months after detoxification.
- Conditions
- Drug-withdrawal., Drug Abuse, Drug-induced Depressive State, AOD Craving
- Trial name
- MADC (NCT01949571)
- Testing
- Mirtazapine (REMERON, Schering-Plough-Organon)
- Where
- Mexico
- Volunteers
- 64 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers.
- Trial name
- PER977-P1 (NCT01826266)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Nicotine Withdrawal, Nicotine Addiction
Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of "tobacco-free" oral nicotine pouches, at various doses and flavors, in healthy adult smokers.
- Conditions
- Nicotine Withdrawal, Nicotine Addiction, Drug Effect
- Trial name
- NCT05335915
- Testing
- Nicotine, Cigarette
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Sleep Architecture Under Opioid Medication
Impairment of Sleep and Pattern of Breathing Before and After Opioid Withdrawal in Comparison to Patients Without Opioid Withdrawal
Main of the study is to assess the influence of high-dose opioids on the sleep architecture and patterns of breathing using non-invasive polysomnographic measurements before and after opioid withdrawal in patient who undergo…
- Trial name
- NCT01540890
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Ruhr University of Bochum
Safety and Pharmacokinetics of Intravenous Baclofen
Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers
The objective of this study is to determine safety and characterize pharmacokinetics of higher doses of intravenous baclofen in healthy subjects.
- Trial name
- NCT01931319
- Testing
- Intravenous baclofen
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Opioid-Related Disorders, Substance Withdrawal Syndrome
Effects of Dynorphin 1-13 on Heroin Addiction - 1
The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses…
- Trial name
- NCT00000244
- Testing
- Dynorphin 1 - 13
- Where
- United States
- Sponsor
- University of Minnesota
MMR on 12 Month
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved dose for 12 months, and then stop…
- Trial name
- NCT05341050
- Testing
- TKI
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- xuna
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06108544
- Testing
- TAK-279, Apremilast
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 1,108 people
- Sponsor
- Takeda
Intoxication, Delirium Tremens (DTs)
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Background and purpose At present, occasional referral to psychiatric or addiction services is the only aftercare option offered following an intoxication/overdose requiring intensive care.
- Conditions
- Intoxication, Delirium Tremens (DTs), Poisoning by Psychoactive Substances, Suicidal Attempt
- Trial name
- NCT07819500
- Testing
- Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Alcohol Withdrawal Syndrome
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS.
- Trial name
- MAGMA (NCT03033823)
- Testing
- Magnesium
- Where
- 11 sites in France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Palliative Care, Withdrawal of Life Support
End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Palliative Care Protocol in the Intensive Care Setting
The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made.
- Conditions
- Palliative Care, Withdrawal of Life Support, Intensive Care Medicine, Sedation
- Trial name
- ARREVE-3 (NCT07368010)
- Testing
- Protocol for palliative care and life-support withdrawal
- Where
- France
- Volunteers
- 720 people
- Sponsor
- Nantes University Hospital
Neonatal Abstinence Syndrome
Physiology and Therapeutic Management of Neonatal Abstinence Syndrome
The overall purpose of this project is to to quantify the physiology of neonatal drug withdrawal and develop non-pharmacological techniques to help improve the therapeutic management of Neonatal Abstinence Syndrome (NAS).
- Trial name
- NCT02768844
- Testing
- Stochastic Vibrotactile Stimulation (SVS), Control
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Massachusetts, Worcester
Alcohol Withdrawal
Osteopathic Treatment to Alcohol Withdrawal Syndrome
The alcohol withdrawal syndrome has a hierarchical symptomatology depending on the severity (minor, moderate or severe). These signs express a state of psychic, behavioral and physical deprivation.
- Trial name
- OSTEOOL (NCT03916939)
- Testing
- osteopathy, simulated osteopathy
- Where
- France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Opioid Withdrawal, Postoperative Pain
Opioid Tapering After Spine Surgery
The effect of a tapering plan combined with telephone counselling to assist patients in opioid tapering after surgery remains unexplored.
- Trial name
- NCT04140955
- Testing
- Tapering plan and telephone counselling
- Where
- Denmark
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Renal Transplant
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants.
- Trial name
- BESTT (NCT00346151)
- Testing
- Belatacept, Sirolimus, Anti-thymocyte globulin
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dexmedetomidine, Midazolam
Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs.
Study will be conducted in Pediatric Intensive Care Unit (PICU) in King Abdullah Specialist Children Hospital (KASCH), National Guard Health Affairs, Riyadh, Saudi Arabia.
- Conditions
- Dexmedetomidine, Midazolam, Withdrawal Symptoms, Failure of Extubation
- Trial name
- PROMISE (NCT05485519)
- Testing
- Dexmedetomidine, Midazolam
- Where
- Saudi Arabia
- Volunteers
- 430 people
- Sponsor
- King Abdullah International Medical Research Center
Alcohol Withdrawal Syndrome
Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome
The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome.
- Trial name
- NCT01652326
- Testing
- Diazepam
- Where
- United States
- Volunteers
- 792 people
- Sponsor
- University of Pittsburgh
Tobacco Dependence, Withdrawal Symptoms
Varenicline OTC Trial on Efficacy and Safety
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
- Conditions
- Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
- Trial name
- VOTC (NCT03557294)
- Testing
- 1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d.
- Where
- 2 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Substance Use Disorders
Substance Use Disorders and Tobacco Habits
In the department for substance use disorders at Uppsala University Hospital there are two wards. One that is locked, where the patients that are emitted can not go out to smoke and another ward where there is a possibility to go…
- Trial name
- NCT03118011
- Testing
- No smoking, Smoking
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Uppsala University